National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 26 of 66
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
NCT01572480
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
NCT01454596
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
NCT01621568
Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
NCT01610570
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
NCT01583686
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
NCT01625156
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
NCT01567709
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
NCT01585428
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01540565
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
NCT01585415
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
NCT01572493
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01533194
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01576172
Clobetasol for Oral Graft-Versus-Host Disease
NCT01557517
FdCyd and THU for Advanced Solid Tumors
NCT01534598
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
NCT01575522
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
NCT01560260
Collection of Transplant Stem Cells for Plasma Cell Myeloma
NCT01547806
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
NCT01507428
Cancer Symptom Data From Multiple Treatment Centers
NCT01547845
AMG 386 and Abiraterone for Advanced Prostate Cancer
NCT01553188
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
NCT01514201
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
NCT01538095
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
NCT01533246
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
NCT01533181
Pazopanib and ARQ 197 for Advanced Solid Tumors
NCT01468922
Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia
NCT01578109
Tivantinib in Treating Patients With Metastatic Prostate Cancer
NCT01519414
Pomalidomide for Kaposi Sarcoma in People With or Without HIV
NCT01495598
Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
NCT01434303
Cancer Vaccine Targeting Brachyury Protein in Tumors
NCT01519817
Testing a Spanish Version of a Patient Toxicity Questionnaire
NCT01517152
Internet-Based and Self-Reports in Assessing Diet and Physical Activity Within AARP
NCT03268577
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
NCT01462695
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
NCT01515176
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
NCT01502410
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
NCT01519427
NHS-IL12 for Solid Tumors
NCT01417546
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01468909
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
NCT01325311
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
NCT01495572
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
NCT01420926
Imaging Study for FdCyd and THU Cancer Treatment
NCT01479348
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
NCT01433913
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
NCT01497431
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
NCT01447914
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01459380
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma
NCT01468311
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
NCT01457131
AZD7451 for Recurrent Gliomas
NCT01468324
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.